Resverlogix Corp. (RVXCF)
| Market Cap | 23.46M +185.6% |
| Revenue (ttm) | n/a |
| Net Income | -6.22M |
| EPS | -0.02 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 100 |
| Open | 0.0700 |
| Previous Close | 0.0700 |
| Day's Range | 0.0700 - 0.0700 |
| 52-Week Range | 0.0250 - 0.2102 |
| Beta | 1.04 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 13, 2026 |
About Resverlogix
Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for patients with chronic illnesses. Its lead drug is apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor for patients with cardiovascular disease, chronic kidney disease, type 2 diabetes mellitus, low high-density lipoprotein, recent acute coronary syndrome, and post COVID-19 conditions. The company has a partnership with Eversana Life Science Services, LLC to support the commercialization of apabetalone for COVID-19 in ... [Read more]
Financial Performance
Financial StatementsNews
Resverlogix Closes US$2 Million Shares-for-Interest Private Placement
Calgary, Alberta--(Newsfile Corp. - May 19, 2026) - Resverlogix Corp. (TSX: RVX) ("Resverlogix") announced today that it has closed a $2,760,057 (US$2,000,000) shares-for-interest private placement (t...
Resverlogix Announces One-Year Extension of Debenture
Calgary, Alberta--(Newsfile Corp. - May 11, 2026) - Resverlogix Corp. (TSX: RVX) ("Resverlogix" or the "Company") announced today a one-year extension of the Company's US$6.0 million secured debenture...
Resverlogix Corp. Announces Filing of Annual Filings and Revocation of MCTO
Calgary, Alberta--(Newsfile Corp. - April 16, 2026) - Resverlogix Corp. (TSX: RVX) ("Resverlogix" or the "Company") announces the revocation, effective April 15, 2026, of a management cease trade orde...
Resverlogix Corp. Announces Issuance of MCTO by ASC
Calgary, Alberta--(Newsfile Corp. - April 2, 2026) - Resverlogix Corp. (TSX: RVX) ("Resverlogix" or the "Company") today announces the issuance of a management cease trade order ("MCTO") by the Albert...
Resverlogix Corp. Provides Bi-Weekly MCTO Status Update
Calgary, Alberta--(Newsfile Corp. - March 31, 2026) - Resverlogix Corp. (TSX: RVX) ("Resverlogix" or the "Company") is providing an update on the management cease trade order ("MCTO") application it m...
Resverlogix Announces Delay in Filing of Annual Financial Statements, AIF, and MD&A
Calgary, Alberta--(Newsfile Corp. - March 17, 2026) - Resverlogix Corp. (TSX: RVX) ("Resverlogix" or the "Company") today announces that because of delays in the completion of its year-end audit, the ...
Resverlogix Closes $2.8 Million Shares-for-Interest Private Placement
Calgary, Alberta--(Newsfile Corp. - February 18, 2026) - Resverlogix Corp. (TSX: RVX) ("Resverlogix") announced today that it has closed a $2.8 million shares-for-interest private placement with an im...
Resverlogix Appoints Bradley Glass to Board of Directors
Calgary, Alberta--(Newsfile Corp. - November 18, 2025) - Resverlogix Corp. (TSX: RVX) ("Resverlogix", or the "Company") today announces the appointment of Mr. Bradley Glass, J.D.
Resverlogix Announces Voting Results from the 2025 Meeting of Shareholders
Calgary, Alberta--(Newsfile Corp. - June 30, 2025) - Resverlogix Corp. (TSX: RVX) ("Resverlogix", or the "Corporation") today held its Annual Meeting of Shareholders (the "Meeting") in Calgary, Albert...
Resverlogix Announces Voting Results from the 2024 Meeting of Shareholders and Closing of Debenture Extension
Calgary, Alberta--(Newsfile Corp. - July 31, 2024) - Resverlogix Corp. (TSX: RVX) ("Resverlogix", or the "Corporation") today held its Annual & Special Meeting of Shareholders (the "Meeting") in Calga...
Resverlogix Provides Update Regarding Two-Year Extension of Debenture and Elimination of Conversion Privileges
Calgary, Alberta--(Newsfile Corp. - July 16, 2024) - Resverlogix Corp. (TSX: RVX) ("Resverlogix" or the "Company") announced it has entered into definitive transaction documents for the two-year exten...
Resverlogix Announces Updated Annual and Special Meeting of Shareholders
Calgary, Alberta--(Newsfile Corp. - May 28, 2024) - Resverlogix Corp. (TSX: RVX) ("Resverlogix" or the "Company") announced today that its Annual and Special Meeting of Shareholders (the "Meeting") wi...
Resverlogix Announces Two-Year Extension of Debenture and Elimination of Conversion Privileges
Calgary, Alberta--(Newsfile Corp. - May 13, 2024) - Resverlogix Corp. (TSX: RVX) ("Resverlogix" or the "Company") announced today a two-year extension of the Company's US$6.0 million secured convertib...
Resverlogix Announces Change to Its Board of Directors
Calgary, Alberta--(Newsfile Corp. - February 21, 2024) - Resverlogix Corp. (TSX: RVX) ("Resverlogix" or the "Company") today announced that Shawn Lu has stepped down from the Board of Directors, effec...
Resverlogix Announces Publication of its 40th Scientific Journal Article on Apabetalone's Potential Therapeutic Benefits
Calgary, Alberta--(Newsfile Corp. - January 11, 2024) - Resverlogix Corp. (TSX: RVX) ("Resverlogix", "the Company") today announced publication of an article, entitled, "The BET inhibitor apabetalone ...
Resverlogix Publishes on Apabetalone's Potential for the Treatment of FSHD, the Third Most Common Muscular Dystrophy
Calgary, Alberta--(Newsfile Corp. - October 4, 2023) - Resverlogix Corp. (TSX: RVX) ("Resverlogix") today announced the publication of a peer-reviewed article, entitled "Apabetalone, a Clinical-stage,...
Resverlogix Announces a Favorable Outlook Based on New Cardiovascular Disease Treatment Guidelines for Patients with Type 2 Diabetes
Amsterdam, Netherlands and Calgary, Alberta--(Newsfile Corp. - August 29, 2023) - Resverlogix Corp. (TSX: RVX) ("Resverlogix") (TSX:RVX) today announced that new guidelines published by the European S...
Resverlogix Announces Warrant Repricing and One-Year Extension
Calgary, Alberta--(Newsfile Corp. - June 29, 2023) - Resverlogix Corp. (TSX: RVX) ("Resverlogix" or the "Company") announces that certain of its 27,461,157 common share purchase warrants (the "Warrant...
Resverlogix Announces Voting Results from the 2023 Meeting of Shareholders
Calgary, Alberta--(Newsfile Corp. - June 20, 2023) - Resverlogix Corp. (TSX: RVX) ("Resverlogix", or the "Corporation") today held its Annual Meeting of Shareholders (the "Meeting") in Calgary, Albert...
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Acquires Additional Securities of Resverlogix Corp.
Calgary, Alberta--(Newsfile Corp. - May 21, 2021) - Shenzhen Hepalink Pharmaceutical Group Co., Ltd. ("Hepalink") announces that on May 13, 2021, it acquired 10% secured convertible debentures due May...
Resverlogix Announces Corporate Update Conference Call & Webcast on June 10, 2020 and Upcoming Presentation at the 57th ERA-EDTA Virtual Congress on June 9, 2020
CALGARY, Alberta, June 05, 2020 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) is pleased to announce the Company will host a Corporate Update Conference Call and W...